By Karen Roman
Biopharmaceutical company ReAlta Life Sciences said it appointed Andrew Miller, Ph.D., to its Board of Directors.
Dr. Miller is the founder of Karuna Therapeutics, acquired by Bristol Myers Squibb for $14 billion in 2024, the company declared.
Additionally, Dr. Miller led the development of FDA-approved schizophrenia treatment COBENFY, it said.
“Andrew’s leadership and strategic insight will help guide ReAlta’s mission to develop transformative therapies for patients with severe inflammatory diseases,” said David Marek, ReAlta’s CEO.
Contact:
